Literature DB >> 24001487

The Mayo Clinic Biobank: a building block for individualized medicine.

Janet E Olson1, Euijung Ryu, Kiley J Johnson, Barbara A Koenig, Karen J Maschke, Jody A Morrisette, Mark Liebow, Paul Y Takahashi, Zachary S Fredericksen, Ruchi G Sharma, Kari S Anderson, Matthew A Hathcock, Jason A Carnahan, Jyotishman Pathak, Noralane M Lindor, Timothy J Beebe, Stephen N Thibodeau, James R Cerhan.   

Abstract

OBJECTIVE: To report the design and implementation of the first 3 years of enrollment of the Mayo Clinic Biobank. PATIENTS AND METHODS: Preparations for this biobank began with a 4-day Deliberative Community Engagement with local residents to obtain community input into the design and governance of the biobank. Recruitment, which began in April 2009, is ongoing, with a target goal of 50,000. Any Mayo Clinic patient who is 18 years or older, able to consent, and a US resident is eligible to participate. Each participant completes a health history questionnaire, provides a blood sample, and allows access to existing tissue specimens and all data from their Mayo Clinic electronic medical record. A community advisory board provides ongoing advice and guidance on complex decisions.
RESULTS: After 3 years of recruitment, 21,736 individuals have enrolled. Fifty-eight percent (12,498) of participants are female and 95% (20,541) of European ancestry. Median participant age is 62 years. Seventy-four percent (16,171) live in Minnesota, with 42% (9157) from Olmsted County, where the Mayo Clinic in Rochester, Minnesota, is located. The 5 most commonly self-reported conditions are hyperlipidemia (8979, 41%), hypertension (8174, 38%), osteoarthritis (6448, 30%), any cancer (6224, 29%), and gastroesophageal reflux disease (5669, 26%). Among patients with self-reported cancer, the 5 most common types are nonmelanoma skin cancer (2950, 14%), prostate cancer (1107, 12% in men), breast cancer (941, 4%), melanoma (692, 3%), and cervical cancer (240, 2% in women). Fifty-six percent (12,115) of participants have at least 15 years of electronic medical record history. To date, more than 60 projects and more than 69,000 samples have been approved for use.
CONCLUSION: The Mayo Clinic Biobank has quickly been established as a valuable resource for researchers.
Copyright © 2013 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  BMI; BRFSS; Behavioral Risk Factor Surveillance System Survey; CAB; Community Advisory Board; DCE; Deliberative Community Engagement; EMR; WBC; body mass index; electronic medical record; white blood cell

Mesh:

Year:  2013        PMID: 24001487      PMCID: PMC4258707          DOI: 10.1016/j.mayocp.2013.06.006

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  28 in total

1.  A comparison of national estimates from the National Health Interview Survey and the Behavioral Risk Factor Surveillance System.

Authors:  David E Nelson; Eve Powell-Griner; Machell Town; Mary Grace Kovar
Journal:  Am J Public Health       Date:  2003-08       Impact factor: 9.308

2.  What makes UK Biobank special?

Authors:  Rory Collins
Journal:  Lancet       Date:  2012-03-31       Impact factor: 79.321

3.  Implementing a public deliberative forum.

Authors:  Kieran O'Doherty; François-Pierre Gauvin; Colleen Grogan; Will Friedman
Journal:  Hastings Cent Rep       Date:  2012 Mar-Apr       Impact factor: 2.683

4.  Informed consent in biobank research: a deliberative approach to the debate.

Authors:  David M Secko; Nina Preto; Simon Niemeyer; Michael M Burgess
Journal:  Soc Sci Med       Date:  2008-12-16       Impact factor: 4.634

5.  Some principles and practices of genetic biobanking studies.

Authors:  A K Macleod; D C M Liewald; M M McGilchrist; A D Morris; S M Kerr; D J Porteous
Journal:  Eur Respir J       Date:  2009-02       Impact factor: 16.671

6.  Biobanks need publicity.

Authors:  George Gaskell; Herbert Gottweis
Journal:  Nature       Date:  2011-03-10       Impact factor: 49.962

7.  A simple method to assess exercise behavior in the community.

Authors:  G Godin; R J Shephard
Journal:  Can J Appl Sport Sci       Date:  1985-09

8.  Age and sex patterns of drug prescribing in a defined American population.

Authors:  Wenjun Zhong; Hilal Maradit-Kremers; Jennifer L St Sauver; Barbara P Yawn; Jon O Ebbert; Véronique L Roger; Debra J Jacobson; Michaela E McGree; Scott M Brue; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2013-06-19       Impact factor: 7.616

9.  Potential bias in the bank: what distinguishes refusers, nonresponders and participants in a clinic-based biobank?

Authors:  J L Ridgeway; L C Han; J E Olson; K A Lackore; B A Koenig; T J Beebe; J Y Ziegenfuss
Journal:  Public Health Genomics       Date:  2013-04-12       Impact factor: 2.000

10.  Population genomics: laying the groundwork for genetic disease modeling and targeting.

Authors:  J Gulcher; K Stefansson
Journal:  Clin Chem Lab Med       Date:  1998-08       Impact factor: 3.694

View more
  105 in total

1.  The senescence-associated secretome as an indicator of age and medical risk.

Authors:  Marissa J Schafer; Xu Zhang; Amanika Kumar; Elizabeth J Atkinson; Yi Zhu; Sarah Jachim; Daniel L Mazula; Ashley K Brown; Michelle Berning; Zaira Aversa; Brian Kotajarvi; Charles J Bruce; Kevin L Greason; Rakesh M Suri; Russell P Tracy; Steven R Cummings; Thomas A White; Nathan K LeBrasseur
Journal:  JCI Insight       Date:  2020-06-18

2.  CORR® ORS Richard A. Brand Award: Disruption in Peroxisome Proliferator-Activated Receptor-γ (PPARG) Increases Osteonecrosis Risk Through Genetic Variance and Pharmacologic Modulation.

Authors:  Cody C Wyles; Christopher R Paradise; Matthew T Houdek; Susan L Slager; Andre Terzic; Atta Behfar; Andre J van Wijnen; Rafael J Sierra
Journal:  Clin Orthop Relat Res       Date:  2019-08       Impact factor: 4.176

3.  Incorporating a Genetic Risk Score Into Coronary Heart Disease Risk Estimates: Effect on Low-Density Lipoprotein Cholesterol Levels (the MI-GENES Clinical Trial).

Authors:  Iftikhar J Kullo; Hayan Jouni; Erin E Austin; Sherry-Ann Brown; Teresa M Kruisselbrink; Iyad N Isseh; Raad A Haddad; Tariq S Marroush; Khader Shameer; Janet E Olson; Ulrich Broeckel; Robert C Green; Daniel J Schaid; Victor M Montori; Kent R Bailey
Journal:  Circulation       Date:  2016-02-25       Impact factor: 29.690

4.  Genetic Risk Score Analysis in Early-Onset Bipolar Disorder.

Authors:  Peter S Jensen; Mark A Frye; Joanna M Biernacka; Paul E Croarkin; Joan L Luby; Kelly Cercy; Jennifer R Geske; Marin Veldic; Matthew Simonson; Paramjit T Joshi; Karen Dineen Wagner; John T Walkup; Malik M Nassan; Alfredo B Cuellar-Barboza; Leah Casuto; Susan L McElroy
Journal:  J Clin Psychiatry       Date:  2017 Nov/Dec       Impact factor: 4.384

5.  Investigating Asthma, Allergic Disease, Passive Smoke Exposure, and Risk of Rheumatoid Arthritis.

Authors:  Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Robert Vassallo; John M Davis
Journal:  Arthritis Rheumatol       Date:  2019-07-01       Impact factor: 10.995

6.  Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol).

Authors:  Suzette J Bielinski; Jennifer L St Sauver; Janet E Olson; Nicholas B Larson; John L Black; Steven E Scherer; Matthew E Bernard; Eric Boerwinkle; Bijan J Borah; Pedro J Caraballo; Timothy B Curry; HarshaVardhan Doddapaneni; Christine M Formea; Robert R Freimuth; Richard A Gibbs; Jyothsna Giri; Matthew A Hathcock; Jianhong Hu; Debra J Jacobson; Leila A Jones; Sara Kalla; Tyler H Koep; Viktoriya Korchina; Christie L Kovar; Sandra Lee; Hongfang Liu; Eric T Matey; Michaela E McGree; Tammy M McAllister; Ann M Moyer; Donna M Muzny; Wayne T Nicholson; Lance J Oyen; Xiang Qin; Ritika Raj; Véronique L Roger; Carolyn R Rohrer Vitek; Jason L Ross; Richard R Sharp; Paul Y Takahashi; Eric Venner; Kimberly Walker; Liwei Wang; Qiaoyan Wang; Jessica A Wright; Tsung-Jung Wu; Liewei Wang; Richard M Weinshilboum
Journal:  Int J Epidemiol       Date:  2020-02-01       Impact factor: 7.196

7.  Returning Results: Let's Be Honest!

Authors:  Bernice S Elger; Eva De Clercq
Journal:  Genet Test Mol Biomarkers       Date:  2017-02-24

8.  CDKN2A Germline Rare Coding Variants and Risk of Pancreatic Cancer in Minority Populations.

Authors:  Robert R McWilliams; Eric D Wieben; Kari G Chaffee; Samuel O Antwi; Leon Raskin; Olufunmilayo I Olopade; Donghui Li; W Edward Highsmith; Gerardo Colon-Otero; Lauren G Khanna; Jennifer B Permuth; Janet E Olson; Harold Frucht; Jeanine Genkinger; Wei Zheng; William J Blot; Lang Wu; Luciana L Almada; Martin E Fernandez-Zapico; Hugues Sicotte; Katrina S Pedersen; Gloria M Petersen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-07-23       Impact factor: 4.254

Review 9.  Biobanks and personalized medicine.

Authors:  J E Olson; S J Bielinski; E Ryu; E M Winkler; P Y Takahashi; J Pathak; J R Cerhan
Journal:  Clin Genet       Date:  2014-03-27       Impact factor: 4.438

10.  Histone H3K27 Trimethylation Modulates 5-Fluorouracil Resistance by Inhibiting PU.1 Binding to the DPYD Promoter.

Authors:  Rentian Wu; Qian Nie; Erin E Tapper; Calvin R Jerde; Garrett S Dunlap; Shikshya Shrestha; Tarig A Elraiyah; Steven M Offer; Robert B Diasio
Journal:  Cancer Res       Date:  2016-08-30       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.